238 related articles for article (PubMed ID: 29596062)
1. Imaging activated T cells predicts response to cancer vaccines.
Alam IS; Mayer AT; Sagiv-Barfi I; Wang K; Vermesh O; Czerwinski DK; Johnson EM; James ML; Levy R; Gambhir SS
J Clin Invest; 2018 Jun; 128(6):2569-2580. PubMed ID: 29596062
[TBL] [Abstract][Full Text] [Related]
2. Radiation Augments the Local Anti-Tumor Effect of
Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
Front Immunol; 2021; 12():763888. PubMed ID: 34868010
[TBL] [Abstract][Full Text] [Related]
3. Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease.
Alam IS; Simonetta F; Scheller L; Mayer AT; Murty S; Vermesh O; Nobashi TW; Lohmeyer JK; Hirai T; Baker J; Lau KH; Negrin R; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4780-4790. PubMed ID: 32900772
[TBL] [Abstract][Full Text] [Related]
4. The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Ruby CE; Weinberg AD
Cancer Immunol Immunother; 2009 Dec; 58(12):1941-7. PubMed ID: 19288101
[TBL] [Abstract][Full Text] [Related]
5. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
Haabeth OAW; Blake TR; McKinlay CJ; Waymouth RM; Wender PA; Levy R
Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9153-E9161. PubMed ID: 30201728
[TBL] [Abstract][Full Text] [Related]
6. Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Pieper AA; Spiegelman DV; Felder MAR; Feils AS; Tsarovsky NW; Zaborek J; Morris ZS; Erbe AK; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2459-2471. PubMed ID: 37016127
[TBL] [Abstract][Full Text] [Related]
7. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine.
Hsieh CL; Chen DS; Hwang LH
Hum Gene Ther; 2000 Mar; 11(5):681-92. PubMed ID: 10757348
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
11. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
12. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
14. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
15. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
17. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
[TBL] [Abstract][Full Text] [Related]
18. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.
Jarosz M; Jazowiecka-Rakus J; Cichoń T; Głowala-Kosińska M; Smolarczyk R; Smagur A; Malina S; Sochanik A; Szala S
Gene Ther; 2013 Mar; 20(3):262-73. PubMed ID: 22495576
[TBL] [Abstract][Full Text] [Related]
20. Making room for T cells.
Maine GN; Mulé JJ
J Clin Invest; 2002 Jul; 110(2):157-9. PubMed ID: 12122106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
